

Maria Rogdaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8466662/publications.pdf>

Version: 2024-02-01

27
papers

1,032
citations

759233

12
h-index

610901

24
g-index

29
all docs

29
docs citations

29
times ranked

1630
citing authors

#	ARTICLE	IF	CITATIONS
1	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. <i>Molecular Psychiatry</i> , 2023, 28, 1995-2006.	7.9	13
2	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. <i>British Journal of Psychiatry</i> , 2022, 221, 740-747.	2.8	6
3	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021, 26, 1332-1345.	7.9	23
4	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2021, 11, 322.	4.8	10
5	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 393.	4.8	27
6	Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106239.	4.7	13
7	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. <i>Molecular Psychiatry</i> , 2020, 25, 1704-1717.	7.9	39
8	S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S102-S103.	4.3	0
9	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. <i>Schizophrenia Bulletin</i> , 2020, 46, S28-S28.	4.3	0
10	Patterns of Cortical Folding Associated with Autistic Symptoms in Carriers and Noncarriers of the 22q11.2 Microdeletion. <i>Cerebral Cortex</i> , 2020, 30, 5281-5292.	2.9	3
11	Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion. <i>Molecular Autism</i> , 2020, 11, 46.	4.9	8
12	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020, 11, 246.	12.8	148
13	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 1040-1051.	1.5	11
14	M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S192-S192.	4.3	0
15	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2019, 85, 79-87.	1.3	54
16	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. <i>Scientific Reports</i> , 2019, 9, 8685.	3.3	17
17	The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 291, 34-41.	1.8	13
18	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. <i>JAMA Psychiatry</i> , 2019, 76, 1074.	11.0	50

#	ARTICLE	IF	CITATIONS
19	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. <i>European Neuropsychopharmacology</i> , 2019, 29, 1333-1342.	0.7	8
20	S84. THE EFFECT OF ANTIPSYCHOTICS ON GLUTAMATE LEVELS IN THE ANTERIOR CINGULATE AND CLINICAL RESPONSE MEASURED BY PANSS: A 1H-MRS STUDY IN FIRST-EPIISODE PSYCHOSIS PATIENTS. <i>Schizophrenia Bulletin</i> , 2019, 45, S339-S339.	4.3	0
21	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. <i>Psychopharmacology</i> , 2019, 236, 1985-1997.	3.1	35
22	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. <i>Molecular Psychiatry</i> , 2019, 24, 1502-1512.	7.9	120
23	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2018, 32, 3-29.	4.0	196
24	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. <i>Schizophrenia Bulletin</i> , 2018, 44, S395-S395.	4.3	1
25	A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 1206.	11.0	178
26	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. <i>Biological Psychiatry</i> , 2016, 80, e19-e20.	1.3	4
27	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. <i>Journal of Psychopharmacology</i> , 2015, 29, 892-897.	4.0	51